Wednesday, May 24, 2017 7:53:42 PM
"Bioelectrics" asked for OTC clearance for all indications. The FDA said "SORRY, we'll clear it for osteoarthritis of the knee and plantar fasciitis ONLY."
The FDA did NOT create a special pathway for the ActiPatch.
The PPS tells us all we need to know about this company and its products. The PPS tsunami never happened. The "FDA News" was a dud.
Anyone who doesn't know why I call the company "Bioelectrics" just needs to listen to the fake paid-for-content "radio interviews" to solve the mystery. Those "interviews" are hilarious.
Looks like the SEC penalties will come due before this product ever gets on a Walgreens shelf.
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM